Press Releases

Filters
August 13, 2020

Debiopharm’s IAP Antagonist Significantly Improves Overall Survival of High-Risk Head & Neck Cancer Patients

Read more
July 7, 2020

Nucleai Secured $6.5m Series-A Initial Closing Led by Debiopharm to Advance Ai-Powered Precision Oncology Platform

Read more
June 10, 2020

Debiopharm’s novel microbiome remodeling program licensed to Takeda for the treatment of gastrointestinal disorders

Read more
June 9, 2020

Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer

Read more
May 26, 2020

Acquisition of Debiopharm’s Investment Portfolio Company Kaiku Health Broadens Patient Access to Digital Oncology Intervention

Read more
April 29, 2020

Le Challenge pour la Qualité de vie du patient 2020 est maintenu et le délai de remise des projets prolongé…

Read more
March 25, 2020

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Read more
March 5, 2020

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

Read more
February 27, 2020

FDA grants Breakthrough Therapy Designation for Debiopharm’s novel chemo-radio sensitizer Debio 1143 for front-line treatment of Head & Neck Cancer

Read more